Liver Cirrhosis - Pipeline Insight, 2024

Liver Cirrhosis - Pipeline Insight, 2024

DelveInsight’s, “Liver Cirrhosis - Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Liver Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Liver Cirrhosis: Understanding

Liver Cirrhosis: Overview

Liver cirrhosis is a condition in which the liver is scarred and permanently damaged, and scar tissue replaces healthy liver tissue, preventing the liver from working normally. Cirrhosis is usually caused by long-term liver damage from conditions such as alcohol-associated liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B. Symptoms of cirrhosis may not appear until the liver is badly damaged and can include fatigue, severe itchy skin, and swelling in the legs and abdomen. Doctors diagnose cirrhosis based on medical history, a physical exam, and the results of tests such as blood tests, imaging tests, and liver biopsy. There is no specific cure for cirrhosis, but treating the underlying causes of cirrhosis may keep it from getting worse and may help prevent liver failure. Complications of cirrhosis can include portal hypertension, infections, and liver cancer. Eating a healthy diet and avoiding foods and drinks that can damage the liver, such as raw shellfish and alcohol, can help manage cirrhosis. In some cases, liver transplant may be an option.

Liver cirrhosis symptoms can vary depending on the severity of the condition. Early symptoms may include fatigue, poor appetite, weight loss, nausea, belly pain, and small red spider-like blood vessels on the skin. As liver function worsens, symptoms may include fluid buildup in the legs and abdomen, yellow color in the skin, mucous membranes, or eyes (jaundice), redness on the palms of the hands, impotence and breast swelling in men, easy bruising and abnormal bleeding, confusion or problems thinking, pale or clay-colored stools, and bleeding from the upper or lower gastrointestinal tract.

Liver cirrhosis diagnosis involves a combination of blood tests, imaging tests, and, in some cases, a liver biopsy. Blood tests can reveal elevated liver enzymes, abnormal liver function, and signs of infection or inflammation. Imaging tests such as ultrasound, CT, or MRI can help visualize the liver and detect any abnormalities. A liver biopsy may be necessary to confirm the diagnosis and assess the severity of the damage.

Treatment for liver cirrhosis focuses on slowing the progression of scar tissue, managing symptoms, and preventing complications. Lifestyle changes may include diet modifications, discontinuing alcohol use, weight loss for those with obesity, regular exercise, and good hygiene to reduce infection risk. Medications may include antiviral medications for viral hepatitis, diuretics to reduce fluid buildup, beta-blockers to prevent bleeding from enlarged veins, and prescription creams for itching.

“Liver Cirrhosis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Liver Cirrhosis pipeline landscape is provided which includes the disease overview and Liver Cirrhosis treatment guidelines. The assessment part of the report embraces, in depth Liver Cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liver Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Liver Cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve Liver Cirrhosis.

Liver Cirrhosis Emerging Drugs Chapters

This segment of the Liver Cirrhosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Liver Cirrhosis Emerging Drugs

• Elafibranor: Ipsen

Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC), and primary sclerosing cholangitis. The drug candidate is administered orally as a coated tablet. It acts by targeting peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta / PPAR- delta. The drug candidate was under development for dyslipidemia, abdominal obesity, type 2 diabetes, Crohn’s disease, insulin resistance and glucose intolerance, colitis and NAFLD/NASH-induced hepatocellular carcinoma (HCC). In December 2023, Ipsen and GENFIT announced that the US Food and Drug Administration (FDA) had accepted the New Drug Application (NDA) for investigational elafibranor.

• Volixibat: Mirum Pharmaceuticals

Volixibat is a minimally absorbed, orally administered investigational therapy designed to selectively inhibit ileal bile acid transporter (IBAT), a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company believes that volixibat may offer a novel approach in the treatment of rare liver diseases impacting both adults and children by blocking the recycling of bile acids, thereby reducing bile acids systemically. Volixibat is currently being studied in intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, and primary biliary cholangitis. Currently, the drug is in Phase II stage of its clinical trial.

• PVT201: Parvus Therapeutics

Parvus Therapeutics, a biopharmaceutical company developing PVT201 drug for the treatment of Primary Biliary Cholangitis. Currently, the drug is in preclinical stage of its development.

Further product details are provided in the report……..

Liver Cirrhosis: Therapeutic Assessment

This segment of the report provides insights about the different Liver Cirrhosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Liver Cirrhosis

There are approx. 45+ key companies which are developing the therapies for Liver Cirrhosis. The companies which have their Liver Cirrhosis drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.

Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Liver Cirrhosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Liver Cirrhosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liver Cirrhosis drugs.

Liver Cirrhosis Report Insights

• Liver Cirrhosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Liver Cirrhosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Liver Cirrhosis drugs?
• How many Liver Cirrhosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Liver Cirrhosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Liver Cirrhosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Liver Cirrhosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Versantis AG
• Mirum Pharmaceuticals
• Sagimet Biosciences
• TenNor Therapeutics
• Prism Pharma
• Vedanta Biosciences
• Intercept Pharmaceuticals
• Boehringer Ingelheim
• Ohara Pharmaceutical
• Ocelot Bio
• Calliditas Therapeutics
• Galecto Biotech
• Pharmicell

Key Products

• Volixibat
• VS-01
• TVB-2640
• TNP-2092
• PRI-724
• VE303
• Obeticholic Acid (OCA)
• BI 685509
• OP-724
• OCE-205
• GKT137831
• GB1211
• Cellgram-LC